Valitor
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2630 Bancroft Way, Berkeley, California,...Phone Number
(510) 545-6062Website
www.valitorbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Valitor
Valitor is a biotechnology company focused on developing innovative ophthalmic medicines using its proprietary multivalent biopolymer technology. The company aims to improve patient outcomes in ophthalmology by creating long-acting treatments for vision-threatening diseases, such as wet age-related macular degeneration (AMD). Valitor's lead candidate, VLTR-559, is designed to provide extended therapeutic durability and reduce the frequency of injections required for effective treatment. The company targets healthcare providers and patients affected by ocular diseases, leveraging its technology to expand its pipeline and explore collaborations in various therapeutic areas.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Valitor your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Valitor, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Valitor launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Valitor has recently received funding, and reach out quickly before it becomes old news!
Check out if Valitor is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Valitor
Website visits: Recent activity has been detected on your website
Click to see if Valitor had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Valitor has new funding data
Earning: See what the market has to say on Valitor recently announced quarterly report
Recommended Actions
Find VP level buyers at Valitor
Find 2 more new buyers
Compare Similar Companies to Valitor
Compare insights from companies similar to Valitor, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Valitor
<$5M
1-10
Private
$28M
2010
N/A
Company Profile Activity
Activity Insights
Valitor is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Valitor is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Valitor.
Valitor financials insights
Gather financial insights about Valitor, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$28M
Valitor Tech Stack
A closer look at the technologies used by Valitor
Most Recent Scoops
Event
Person-Based
Mergers & Acquisitions, Events, Business Development, Pharmaceuticals, Podcast
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Left Company
Executive Move
Left Company
Executive Move
Valitor News & Media
Valitor to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory D. Kunst will share a company overview describing Valitor’s platform technology and pipeline in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026 at 8:00 a.m. ET.Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD
VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dose for treatment of wet age-related macular degenerationValitor to Participate in the 25th Annual Needham Virtual Healthcare Conference
BERKELEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory D. Kunst will share a company overview describing Valitor’s platform technology and pipeline in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET.Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
BERKELEY, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the company will present new preclinical data highlighting the potential of VLTR-559, a long-acting anti-VEGF biologic designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD), in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on Sunday, May
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Valitor
Sign Up For FreeTo access detailed company insights
Valitor is a biotechnology company focused on developing innovative ophthalmic medicines using its proprietary multivalent biopolymer technology. The company aims to improve patient outcomes in ophthalmology by creating long-acting treatments for vision-threatening diseases, such as wet age-related macular degeneration (AMD). Valitor's lead candida... Read More
